← Scoopfeeds — Intelligent news, curated.
Goldman Sees Limited Upside for Dr. Reddy’s Laboratories Limited (RDY) Amid Generic Drug Concerns
business

Goldman Sees Limited Upside for Dr. Reddy’s Laboratories Limited (RDY) Amid Generic Drug Concerns

Yahoo Finance · May 11, 2026, 8:06 PM · Also reported by 1 other source

Goldman Sees Limited Upside for Dr. Reddy’s Laboratories Limited (RDY) Amid Generic Drug Concerns

Read full story on Yahoo Finance → More top stories

Also covered by

ARY News Dr Reddy’s plans generic Ozempic launch in Canada

More in business

Bloomberg Markets
Blackstone Drops $4 Billion New World Deal Over Control Clash
Investing.com
Bank of America raises AI data center market forecast to $1.7 trillion by 2030
Investing.com
Earnings call transcript: Ceconomy AG Q2 2026 shows robust growth and strategic progress
Investing.com
Wix.Com Ltd earnings missed by $0.54, revenue fell short of estimates
Investing.com
Earnings call transcript: Axon Enterprise Q1 2026 beats forecasts with strong growth
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop